ABIOMED Inc. is commencing its pilot clinical trial in the U.S. for the IMPELLA 2.5 minimally invasive ventricular assist device (VAD) after recent FDA approval. The approval is conditioned upon the company’s submission of additional information to the FDA within a limited time frame.
The Impella Recover 2.5, an investigational device, allows the heart to rest and recover by actively unloading the ventricle, reducing myocardial workload and oxygen consumption while increasing cardiac output, coronary and end-organ perfusion.
